Real-life assessment of treatment outcomes with everolimus and exemestane after cyclin-dependent kinase 4/6 inhibitor use in hormone receptor-positive metastatic breast cancer in a tertiary United Kingdom cancer center
INTRODUCTION: Everolimus and exemestane (EXE+E) have been used for patients with metastatic hormone receptor-positive breast cancer who progress on nonsteroidal aromatase inhibitor (NSAI) treatment, since the BOLERO-2 trial in 2011-12. The patient population in BOLERO 2 had previous treatments with...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Via Medica
2026-07-01
|
| Edice: | Oncology in Clinical Practice |
| Témata: | |
| On-line přístup: | https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106191 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|